|
WO2021001525A1
|
|
Process for purifying c1-inh
|
|
CA3115393A1
|
|
Process for purifying c1-inh
|
|
CA3072003A1
|
|
Method for virus filtration of von willebrand factor
|
|
BR112019012772A2
|
|
blood clotting factor replacement product for use in the treatment or prophylaxis of bleeding
|
|
WO2018037046A1
|
|
Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
|
|
CN109562149A
|
|
The pharmaceutical preparation of c1 esterase inhibitor
|
|
CA2977090A1
|
|
Pharmaceutical formulations of c1 esterase inhibitor
|
|
US2017209546A1
|
|
Improved factor viii preparations suitable for therapeutic use and processes to obtain these
|
|
AU2015276089A1
|
|
Therapy using a Factor XII inhibitor in a neurotraumatic disorder
|
|
US2016166660A1
|
|
Combination therapy using a factor xii inhibitor and a c-1 inhibitor
|
|
AU2014224599A1
|
|
Treatment and prevention of remote ischemia-reperfusion injury
|
|
US2016008425A1
|
|
Therapeutic agent for amniotic fluid embolism
|
|
SG10201911709RA
|
|
A method of purifying therapeutic proteins
|
|
AU2013202565A1
|
|
Therapeutic application of Kazal-type serine protease inhbitors
|
|
AU2013202564A1
|
|
Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
|
|
AU2013202566A1
|
|
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
|
AU2013202563A1
|
|
Method of increasing the in vivo recovery of therapeutic polypeptides
|
|
JP2014162789A
|
|
Therapeutic agent for amniotic fluid embolism
|
|
EP2814502A1
|
|
Von willebrand factor variants having improved factor viii binding affinity
|
|
US2014371425A1
|
|
Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
|
